|Daily Range||$138.49 - $141.29|
|52-Week Range||$124.36 - $150.63|
|Dividend (Yield)||$0.00 (1.5%)|
|Average Daily Volume||47,403|
|Current FY EPS||$7.51|
The iShares MSCI EAFE Exchange Traded Fund offers instant international diversification among top companies in top countries for a reasonably low overhead cost.
Three Motley Fool analysts tell investors which biotechnology stocks are on their wish list this month.
Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
As if people didn’t hate Monsanto enough, they’re now going against the EPA and further harming this crucial insect.
Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.
The over-the-counter drug market could grow to reach $70 billion in sales by 2015, but according to Brand Keys, this OTC pain reliever is lagging far behind its peers in terms of customer loyalty.
Though not earth-shattering, the largest study to date represents a continued move away from chemical use.
Regeneron recently got some good news. Check out the video below for more information.
Intel, Caterpillar, and Merck were the Dow's best performers in the first half of 2014. Why did these three stocks race ahead, and where are they going next?